NDAC in '01
This article was originally published in The Tan Sheet
Executive Summary
Tentative Dec. 7-8 meeting cancelled; next scheduled meeting date is May 10-11, 2001. NDAC evaluated five subjects in 2000. In July, the committee considered issues related to the relaunch of the Today Sponge by Allendale Pharmaceuticals and the Rx-to-OTC switch applications for cholesterol-lowering statin drugs Mevacor (Merck) and Pravachol (Bristol-Myers Squibb). In October, NDAC met to discuss phenylpropanolamine use in cough/cold and weight loss products, as well as AstraZeneca/P&G's switch application for the proton pump inhibitor Prilosec
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning